1. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral ® ) in organ transplantation. Drugs. 2001;61(13):1957–2016.
2. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet. 1999;353(9158):1083–1091.
3. Noble S, Markham A. Cyclosporine: a review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral ® ). Drugs. 1995;50(5):924–941.
4. Czogalla A. Oral cyclosporine A – the current picture of its liposomal and other delivery systems. Cell Mol Biol Lett. 2009;14(1):139–152.
5. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev. 1997;27(2–3):201–214.
6. Guo JX, Ping QN, Chen Y. Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and sandimmun neoral. Int J Pharm. 2001;216(1–2):17–21.
7. Müller RH, Runge S, Ravelli V, Mehnert W, Thünemann AF, Souto EB. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN ® ) versus drug nanocrystals. Int J Pharm. 2006;317(1):82–89.
8. Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Kumar M. PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral ® . J Control Release. 2007;119(2):197–206.
9. Dai JD, Nagai T, Wang XQ, Zhang T, Meng M, Zhang Q. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int J Pharm. 2004;280(1–2):229–240.
10. Wang XQ, Huang J, Dai JD, et al. Long-term studies on the stability and oral bioavailability of cyclosporine A nanoparticle colloid. Int J Pharm. 2006;322(1–2):146–153.
11. Hermida LG, Sabés-Xamaní M, Barnadas-Rodríguez R. Combined strategies for liposome characterization during in vitro digestion. J Liposome Res. 2009;19(3):207–219.
12. Andrieux K, Forte L, Lesieur S, Paternostre M, Ollivon M, Grabielle-Madelmont C. Solubilisation of dipalmitoylphosphatidylcho- line bilayers by sodium taurocholate: A model to study the stability of liposomes in the gastrointestinal tract and their mechanism of interaction with a model bile salt. Eur J Pharm Biopharm. 2009;71(2):346–355.
13. Werle M, Takeuchi H. Chitosan-aprotinin coated liposomes for oral peptide delivery: Development, characterisation and in vivo evaluation. Int J Pharm. 2009;370(1–2):26–32.
14. Amin M, Jaafari MR, Tafaghodi M. Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits. Colloid Surface B. 2009;74(1):225–229.
15. Park HJ, Lee CM, Lee YB, Lee KY. Controlled release of cyclosporin A from liposomes-in-microsphere as an oral delivery systems. Biotechnol Bioproc Eng. 2006;11(6):526–529.
16. Lee J-S, Chung D, Lee HG. Preparation and characterization of calcium pectinate gel beads entrapping catechin-loaded liposomes. Int J Biol Macromol. 2008;42(2):178–184.
17. Conacher M, Alexander J, Brewer JM. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine. 2001;19(20–22):2965–2974.
18. Senior K. Bilosomes: the answer to oral vaccine delivery? Drug Discov Today. 2001;6(20):1031–1032.
19. Shukla A, Khatri K, Gupta PN, Goyal AK, Mehta A, Vyas SP. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J Pharm Pharmaceut Sci. 2008;11(1):58–66.
20. Mann JFS, Ferro VA, Mullen AB, et al. Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin. Vaccine. 2004;22(19):2425–2429.
21. Chen YP, Lu Y, Chen JM, et al. Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. Int J Pharm. 2009;376(1–2):153–160. 
22. Hildebrand A, Beyer K, Neubert R, Garidel P, Blume A. Temperature dependence of the interaction of cholate and deoxycholate with fluid model membranes and their solubilization into mixed micelles. Colloid Surface B. 2003;32(4):335–351.
23. Clark MA, Jepson MA, Hirst BH. Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev. 2001;50(1–2):81–106.
24. Tang N, Lai J, Chen Y, Lu Y, Wu W. Fenofibrate solid dispersion pel- lets prepared by fluid-bed coating: physical characterization, improved dissolution and oral bioavailability in beagle dogs. J Chin Pharm Sci. 2009;18:156–161.
25. Yu LX, Amidon GL, Polli JE, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res. 2002; 19(7):921–925.
26. Liu C, Wu JH, Shi B, Zhang YX, Gao TK, Pei YY. Enhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxy- ethylene (40) stearate. Drug Dev Ind Pharm. 2006;32(1):115–123.